News

Cambridge, United Kingdom and Shanghai, China, October 28, 2026 – Mundipharma and ShanZeBIO today announced that parties have entered into a strategic licensing agreement for REZZAYO® / XIUNIS® (rezafungin acetate) in Mainland China, Hong Kong and Macau. This agreement will support access to REZZAYO® / XIUNIS® for eligible patients across the region. Under the agreement, ShanZeBIO holds the exclusive licence to register, develop and commercialise REZZAYO® / XIUNIS® in Mainland China, Hong Kong and Macau and will lead commercialisation across the region with an experienced team of anti-infectives specialists. “This strategic licensing arrangement reflects our commitment to expanding access to innovative medicines where they can make a meaningful difference for patients,” said Marc Princen, CEO, Mundipharma. “ShanZeBIO brings deep local expertise, a dedicated anti-infectives strategy and the commercial capabilities to support REZZAYO® / XIUNIS® across the region. Together, we believe this collaboration can help ensure appropriate patients have access to an important treatment option while allowing Mundipharma to maintain focus on our strategic priorities in China.” “This partnership with Mundipharma reflects a shared commitment to addressing unmet medical needs in anti-infectives in Mainland China, Hong Kong and Macau,” said Jin Xiaodong, CEO, ShanZeBIO. “Our medical expertise and proven commercial capabilities position us to deliver the full value of REZZAYO® / XIUNIS® to patients

The partnership will support the continued availability of Avelox® across Asia-Pacific, the Middle East, Africa and Europe through Clinigen’s international commercial and distribution infrastructure. SINGAPORE, 23 September 2026 – Clinigen, a global speciality pharmaceutical services company, and ShanZeBIO, a specialised platform company dedicated to the acquisition, introduction and commercialisation of innovative pharmaceutical products, today announced an exclusive commercialisation and distribution partnership for Avelox® (moxifloxacin) across 16 international markets spanning Asia-Pacific, the Middle East, Africa and Europe. Under the agreement, Clinigen will be responsible for the commercialisation and distribution of Avelox® in the agreed territories, drawing on its capabilities across regulatory affairs, supply chain management, commercial operations and speciality pharmaceutical distribution. ShanZeBIO will provide product supply and pharmaceutical expertise to support implementation of the partnership. The agreement reflects the important role that specialised commercial and distribution partners can play in supporting the long-term availability of established medicines. While many products continue to be relied upon by healthcare systems years after their initial launch, maintaining their presence across geographically diverse markets requires ongoing commercial support, regulatory oversight and supply-chain infrastructure. By combining ShanZeBIO’s pharmaceutical expertise with Clinigen’s international platform and market knowledge, the companies will work together to support the continued availability of Avelox®

September 3, 2026, Shanghai – ShanZeBIO today officially announced that, through close collaboration with Clinigen, a leading global pharmaceutical services provider, it has successfully obtained the Marketing Authorization (MA) for Avelox in Singapore. This is the first MA transfer for ShanZeBIO since it reached an agreement with Bayer on the global rights to Avelox this February, marking the company’s official acquisition of full and independent rights to the product, and the full-scale launch of Avelox’s global operations with innovator quality and standards. ShanZeBIO is a specialized platform company invested by HSG and dedicated to the acquisition, introduction and commercialization of innovative pharmaceutical products from around the world. From rights transfer to the completion of the first overseas market access, the company took only half a year, fully demonstrating ShanZeBIO’s comprehensive capabilities in rapid market access, full product lifecycle management, and global operations. This MA transfer in Singapore also marks a significant milestone for ShanZeBIO in its independent operation and internationalization strategy for Avelox – formally gaining autonomous management control over the entire process from manufacturing and logistics to distribution, ensuring uniform global product management with high-standard quality systems, and setting a benchmark for the company’s future in-licensing and operation of more global

On July 9, 2026, the National Health Commission, together with multiple authorities, issued the National Essential Drug List (2026 Edition), covering a total of 794 medicines¹. Thanks to its outstanding clinical value in anti-infective therapy, Avelox (moxifloxacin hydrochloride tablets/sodium chloride injection) remains on the new edition of the National Essential Drug List. Twenty-Four Years of Journey in China Continued Recognition from Market Launch to Inclusion in the National Essential Drug List Over the past 24 years, Avelox has benefited numerous patients with infectious diseases in China. Moxifloxacin was first included in the National Essential Drug List in 2018. Its continued inclusion in the 2026 Edition represents ongoing recognition of its clinical value, safety and accessibility. Launched in over 100 countries and regions worldwide, and in China in 2002​ ​Has benefited over 240 million patients globally​ Supported by hundreds of large-scale international studies, involving 950,000 patients​ A total of 7,427 medical research papers related to Avelox® have been published worldwide​ In July 2008, the European Medicines Agency approved Avelox® as monotherapy for pelvic inflammatory disease​ In August 2008, the China National Medical Products Administration (NMPA) approved Avelox® as monotherapy for complicated intra-abdominal infections​ In 2018, the China National Medical Products Administration

Recently, HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD.  and its parent company, Ascenda Pte. Ltd. (hereinafter referred to as ShanZeBIO), formally signed a strategic cooperation agreement for import distribution with Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (hereinafter referred to as SPH Kyuan Trade). The two parties announced that they will engage in in-depth cooperation centered on ShanZeBIO’s key product, Moxifloxacin Hydrochloride and Sodium Chloride Injection (brand name: Avelox®). Avelox®  is a fluoroquinolone antibiotic that was first approved for marketing in Europe and the United States in 1999 and entered the Chinese market in 2002; it has served Chinese patients for over 20 years to date. Currently, this product has benefited more than 240 million patients in over 100 countries worldwide. The establishment of this strategic partnership marks an important beginning for the two parties to deepen their cooperation in the Chinese pharmaceutical market. SPH Kyuan Trade will fully leverage its comprehensive capabilities in import customs clearance, warehousing and distribution, market access, and channel expansion to help Avelox® serve Chinese medical institutions and patients more efficiently and reliably, and will partner with ShanZeBIO to promote the sustainable development of high-quality pharmaceutical products in China. About HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. ShanZeBIO

(Singapore/Shanghai | February 2, 2026) HSG announced that on February 2, 2026, it officially completed the global acquisition of the business and assets related to moxifloxacin (brand name: Avelox®), a core fluoroquinolone antibiotic product, and established HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. (Hereinafter referred to as “ShanZeBIO“), an innovative biopharmaceutical company focused on anti-infectives, respiratory diseases and critical care, along with its parent company Ascenda Pte. Ltd., to manage this business. Under the agreement, ShanZeBIO and its parent company, Ascenda Pte. Ltd., acquired specific global assets related to Avelox®, including drug registration certificates, intellectual property rights, and business contracts in relevant countries and regions, laying a solid foundation for the product’s continued supply and future development in global markets. Avelox® is a fluoroquinolone antibiotic first approved in Europe and the United States in 1999. It is currently sold in more than 100 countries worldwide in tablet or intravenous injection form and is used to treat various bacterial infections, including community-acquired pneumonia, skin infections, sinusitis, and chronic bronchitis. For more than two decades, Avelox® has enjoyed the trust of both physicians and patients, achieving widespread clinical recognition and generating substantial revenue in the Chinese market. This acquisition marks a significant step in